Invesco Mortgage Capital Inc. Announces Quarterly Common and Series A Preferred Stock Dividends
Get Alerts IVR Hot Sheet
Join SI Premium – FREE
ATLANTA, June 17, 2019 /PRNewswire/ -- Invesco Mortgage Capital Inc. (NYSE: IVR) today announced that its Board of Directors declared quarterly dividends on shares of its common stock and Series A preferred stock.
Common Stock Dividend
The Company's Board of Directors declared a cash dividend of $0.45 per share of common stock for the second quarter of 2019. The dividend will be paid on July 26, 2019 to stockholders of record on June 28, 2019, with an ex-dividend date of June 27, 2019.
Series A Preferred Stock Dividend
The Board of Directors declared a quarterly cash dividend on its 7.75% Series A Cumulative Redeemable Preferred Stock of $0.4844 per share. The dividend will be paid on July 25, 2019 to stockholders of record on July 1, 2019, with an ex-dividend date of June 28, 2019.
About Invesco Mortgage Capital Inc. Invesco Mortgage Capital Inc. is a real estate investment trust that focuses on investing in, financing and managing residential and commercial mortgage-backed securities and mortgage loans. Invesco Mortgage Capital Inc. is externally managed and advised by Invesco Advisers, Inc., a subsidiary of Invesco Ltd. (NYSE: IVZ), a leading independent global investment management firm. Additional information is available at www.invescomortgagecapital.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/invesco-mortgage-capital-inc-announces-quarterly-common-and-series-a-preferred-stock-dividends-300869666.html
SOURCE Invesco Mortgage Capital Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- E Source completes Phase 1 of Integrated Energy Data Resource Platform for the State of New York, begins work on Phase 2
- BOK Financial Corporation Reports Quarterly Earnings of $84 million, or $1.29 Per Share, in the First Quarter
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!